There are 2949 resources available
403MO - Atezolizumab in combination with bevacizumab for patients with unresectable/metastatic anal cancer
Presenter: Van Morris
Session: Mini Oral - Gastrointestinal tumours, colorectal
Resources:
Abstract
Slides
Webcast
404MO - Clinical relevance of MIR27A rs895819 polymorphism and its interaction with DPYD variants for predicting grade 4-5 fluoropyrimidine (FP) toxicity (tox) in the FUSAFE individual patient data meta-analysis (IPD-MA)
Presenter: Marie-Christine Etienne-Grimaldi
Session: Mini Oral - Gastrointestinal tumours, colorectal
Resources:
Abstract
Slides
Webcast
405MO - Personalized circulating tumour DNA assay for the detection of minimal residual disease in CRC patients after resection of metastases
Presenter: Fotios Loupakis
Session: Mini Oral - Gastrointestinal tumours, colorectal
Resources:
Abstract
Slides
Webcast
406MO - Sequencing paired tumor DNA and white blood cells (WBCs) increases sensitivity to track plasma circulating tumor DNA (ctDNA) for detecting minimal residual disease (MRD) in localized colon cancer (CC)
Presenter: Noelia Tarazona
Session: Mini Oral - Gastrointestinal tumours, colorectal
Resources:
Abstract
Slides
Webcast
LBA56 - ORIENT-12: Sintilimab plus gemcitabine and platinum (GP) as first-line (1L) treatment for locally advanced or metastatic squamous non-small-cell lung cancer (sqNSCLC)
Presenter: Caicun Zhou
Session: Mini Oral - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
LBA57 - MHC-II antigen presentation pathway as a predictive biomarker for sintilimab plus chemotherapy in first-line treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (nsq-NSCLC)
Presenter: Yunpeng Yang
Session: Mini Oral - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
1260MO - Activity of OSE-2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (ICI): Step 1 results of phase III ATALANTE-1 randomised trial
Presenter: Giuseppe Giaccone
Session: Mini Oral - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
LBA58 - ORR in patients receiving nivolumab plus radiotherapy in advanced non-small cell lung cancer: First results from the FORCE trial
Presenter: Farastuk Bozorgmehr
Session: Mini Oral - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
LBA59 - First-line nivolumab (NIVO) + ipilimumab (IPI) combined with 2 cycles of platinum-based chemotherapy (chemo) vs 4 cycles of chemo in advanced non-small cell lung cancer (NSCLC): Patient-reported outcomes (PROs) from CheckMate 9LA
Presenter: Martin Reck
Session: Mini Oral - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
LBA60 - ZENITH20, a multinational, multi-cohort phase II study of poziotinib in NSCLC patients with EGFR or HER2 exon 20 insertion mutations
Presenter: Mark Socinski
Session: Mini Oral - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast